作者: Michael J. Morris , Timothy Akhurst , Steven M. Larson , Marisa Ditullio , Elaina Chu
DOI: 10.1158/1078-0432.CCR-04-2034
关键词:
摘要: Purpose: Standard imaging studies are limited as outcome measures for patients with metastatic prostate cancer. We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve an measure castrate cancer treated antimicrotubule chemotherapy. Experimental Design: FDG-PET were done at baseline, 4, and 12 weeks of treatment. The average maximum standardized uptake value (SUVmaxavg) was measured in up to five lesions quantitative measure. Prostate-specific antigen (PSA) 4 PSA, bone scan, soft tissue considered standard measures. change SUVmaxavg distinguished clinically assessed progression from nonprogression sought. Results: Twenty-two PET reviewed compared PSA weeks; 18 PETs Applying Working Group Consensus Criteria guideline a 25% increase constitutes SUVmaxavg, correctly identified clinical status 20 22 (91%) 17 (94%). accuracy could be further optimized if >33% used define progression. Conclusion: is promising As single modality, it show treatment effects usually described by combination scintigraphy, imaging. Preliminarily, or appearance new lesion optimally dichotomizes progressors nonprogressors.